IRIS UniCatt

Rossi, Elena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.097
AS - Asia 2.496
EU - Europa 2.492
SA - Sud America 470
AF - Africa 78
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 8.648
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.006
SG - Singapore 1.404
DE - Germania 703
CN - Cina 560
SE - Svezia 447
IT - Italia 411
BR - Brasile 391
FR - Francia 168
UA - Ucraina 143
GB - Regno Unito 129
IE - Irlanda 125
PL - Polonia 116
IN - India 97
VN - Vietnam 94
ID - Indonesia 85
FI - Finlandia 62
RU - Federazione Russa 59
CA - Canada 45
HK - Hong Kong 34
IQ - Iraq 34
AR - Argentina 32
AT - Austria 31
MX - Messico 30
KR - Corea 22
BD - Bangladesh 20
ZA - Sudafrica 20
JP - Giappone 19
SA - Arabia Saudita 19
TR - Turchia 18
CI - Costa d'Avorio 16
BE - Belgio 15
ES - Italia 15
NL - Olanda 14
PK - Pakistan 13
IR - Iran 11
LT - Lituania 10
VE - Venezuela 10
AU - Australia 9
CL - Cile 9
KE - Kenya 9
UZ - Uzbekistan 9
PE - Perù 8
CH - Svizzera 7
EC - Ecuador 7
MA - Marocco 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 6
MY - Malesia 6
UY - Uruguay 6
DZ - Algeria 5
KZ - Kazakistan 5
TH - Thailandia 5
CO - Colombia 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
EG - Egitto 4
JO - Giordania 4
LV - Lettonia 4
PH - Filippine 4
RO - Romania 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
EE - Estonia 3
JM - Giamaica 3
OM - Oman 3
BY - Bielorussia 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GA - Gabon 2
HU - Ungheria 2
IL - Israele 2
KG - Kirghizistan 2
LB - Libano 2
MM - Myanmar 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
PY - Paraguay 2
SN - Senegal 2
TW - Taiwan 2
AD - Andorra 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CG - Congo 1
DM - Dominica 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
KH - Cambogia 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
Totale 8.639
Salva come PNG Salva come JPEG
Città #
Singapore 801
Chandler 485
Ashburn 302
Dallas 154
Beijing 119
Dublin 119
Wilmington 94
Rome 88
New York 86
San Mateo 86
Warsaw 86
Jacksonville 85
Fairfield 80
Jakarta 79
Los Angeles 76
Munich 76
Milan 67
Ann Arbor 66
Houston 62
Boston 61
Cattolica 61
Dearborn 61
Nanjing 61
Hefei 60
Woodbridge 56
Seattle 43
São Paulo 42
Marseille 39
Moscow 39
Princeton 38
Chicago 36
Frankfurt am Main 35
Hong Kong 34
Hyderabad 33
Redwood City 32
Hanoi 30
Ho Chi Minh City 27
Lawrence 26
Nürnberg 25
Detroit 23
Kraków 23
Redmond 23
Nanchang 22
Nuremberg 21
Buffalo 20
Cambridge 20
Boardman 18
Bologna 18
Hangzhou 18
Toronto 18
Hebei 17
London 17
Seoul 17
Abidjan 16
Orem 16
Washington 16
Belo Horizonte 15
Brooklyn 15
Brussels 15
Kent 15
The Dalles 15
Vienna 15
Helsinki 14
Leawood 14
Mexico City 14
Norwalk 14
Montreal 13
Santa Clara 13
Tokyo 13
Lappeenranta 11
Paris 11
Stockholm 11
Tianjin 11
Atlanta 10
Changsha 10
Chennai 10
Düsseldorf 10
Ealing 10
Florence 10
Baghdad 9
Bremen 9
Buenos Aires 9
Dhaka 9
Johannesburg 9
Mountain View 9
Rio de Janeiro 9
San Diego 9
Tashkent 9
Bexley 8
Pune 8
Turku 8
Campinas 7
Cape Town 7
Erbil 7
Guangzhou 7
Kunming 7
Portsmouth 7
Riyadh 7
University Park 7
Baku 6
Totale 4.629
Salva come PNG Salva come JPEG
Nome #
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization 315
Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. 308
Haemostatic alterations induced by treatment with asparaginases and clinical consequences 229
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis 216
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 199
Fondaparinux in pregnancy: Could it be a safe option? A review of the literature. 188
Risk factor and etiology analysis of ischemic stroke in young adult patients 182
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 178
Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms : Long-Term Experience. 169
Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment 163
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments 148
Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms 147
Venous thromboembolism in multiple myeloma 144
Contractile reserve of dysfunctional myocardium after revascularization: A dobutamine stress echocardiography study 141
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 140
Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia 136
Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms 135
Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms 134
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls 125
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 124
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 124
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 124
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 124
JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis 123
Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation 121
The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia 120
Assessment of congenital neutropenia in children: common clinical sceneries and clues for management 119
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 118
Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease 118
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 117
Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities 116
Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation 114
Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment 113
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists 113
Inherited thrombophilia: treatment during pregnancy. 111
In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband 111
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 108
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 101
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 99
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population 99
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 96
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia 95
Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups 95
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 94
Reassessment of contractile reserve after revascularization of akinetic myocardium 92
Isolated light chain deposition disease neuropathy in a patient with multiple myeloma 91
Predicting Factors for Seizures after Cerebral Venous Thrombosis: A Retrospective Single Center Cohort Study 86
Structural analysis of protein Z gene variants in patients with foetal losses 84
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases 84
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years 81
Cerebral sinus-venous thrombosis 78
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls 78
Venous thromboembolism in patients with liver diseases 78
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 78
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 78
Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia 78
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 74
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study 74
Glycoprotein la C807T qene polymorphism and increased risk of recurrent acute coronary syndromes: A five year follow up 74
Venous thromboembolism in patients with liver diseases 72
Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis? 72
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 71
G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 69
Predicting Factors for Seizures after Cerebral Venous Thrombosis: A Retrospective Single Center Cohort Study 68
G20210A protrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 68
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial 64
Methylation Analysis of Urinary Sample in Non-Muscle-Invasive Bladder Carcinoma: Frequency and Management of Invalid Result 64
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 64
Second cancers in MPN: Survival analysis from an international study 64
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 63
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 62
Risk factor and etiology analysis of ischemic stroke in young adult patients 61
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 60
Coagulopathy in CAR-T: Critical concern or mere blip? 60
Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms 60
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus 58
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 54
Glycoprotein IA C807T gene polymorphism and increased risk of recurrent acute coronary syndromes: a five year follow up. 49
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 48
Left atrial myxoma supplied from the right coronary artery 41
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 38
ROLE OF 18 F-FDG PET/CT IN THE ASSESSMENT OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA 38
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study 10
Totale 8.780
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.234
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021284 0 0 0 0 0 37 53 22 56 26 76 14
2021/2022668 46 35 16 40 32 13 20 80 45 45 121 175
2022/20231.356 203 197 115 199 77 159 79 84 154 25 35 29
2023/2024742 28 177 30 52 34 127 37 40 14 31 80 92
2024/20251.552 26 67 91 62 121 37 59 71 254 165 325 274
2025/20262.496 601 120 319 416 916 124 0 0 0 0 0 0
Totale 8.780